This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a solution inside single-dose prefilled pens and syringes, given as a subcutaneous injection.

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

This makes the new indication for Dupixent very important for Sanofi as it searches for a blockbuster to transform its fortunes. The FDA is set to make a decision on Dupixent’s new indication on ...

Dupixent is the second drug to gain approval as a COPD treatment this year. In July, the FDA signed off on Verona Pharma's ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Dupixent (dupilumab) was the first biologic medicine to get approval for atopic dermatitis in 2017, and since then has grown sales to more than $2 billion last year, with Sanofi suggesting it ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...